Probiotics Regulate the Expression of COX-2 in Intestinal Epithelial Cells
Overview
Oncology
Authors
Affiliations
Cyclooxygenase-2 (COX) 2 promotes intestinal wound healing but elicits also proinflammatory effects and has been implicated in colorectal carcinogenesis. Thus, a balanced expression of COX-2 is essential for intestinal homeostasis. This study was designed to evaluate the regulation of COX-2 by probiotic organisms and to characterize ligands and receptors involved. Colo320 and SW480 intestinal epithelial cells (IEC) were stimulated with gastrin or TNF-alpha and pre- or coincubated with commensales, bacterial supernatants, or distinct toll-like receptor (TLR) ligands. COX-2 promoter activity was determined by luciferase assays, protein expression by Western blotting, and secretion of prostaglandin E(2) (PGE(2)) by ELISA. Commensales differentially regulated COX-2 expression in IEC. E. coli Nissle 1917, the probiotic mixture VSL#3, and media conditioned by these organisms ameliorated induced COX-2 expression and PGE(2) secretion. Heat inactivation and DNase treatment significantly decreased these regulatory capacities. Lactobacillus acidophilus, however, significantly increased COX-2 expression and PGE(2) secretion. TLR agonists differentially ameliorated basal or induced COX-2 expression. Distinct probiotics specifically and significantly decrease induced COX-2 expression in IEC, most likely mediated by released factors and in part by bacterial DNA. A significant involvement of TLRs in these regulatory processes remains to be established.
Alkushi A, Elazab S, Abdelfattah-Hassan A, Mahfouz H, Salem G, Sheraiba N Pharmaceutics. 2022; 14(6).
PMID: 35745756 PMC: 9228487. DOI: 10.3390/pharmaceutics14061183.
Alkushi A, Abdelfattah-Hassan A, Eldoumani H, Elazab S, Mohamed S, Metwally A Sci Rep. 2022; 12(1):5116.
PMID: 35332200 PMC: 8948303. DOI: 10.1038/s41598-022-08915-5.
An Update on the Effects of Probiotics on Gastrointestinal Cancers.
Davoodvandi A, Fallahi F, Tamtaji O, Tajiknia V, Banikazemi Z, Fathizadeh H Front Pharmacol. 2022; 12:680400.
PMID: 34992527 PMC: 8724544. DOI: 10.3389/fphar.2021.680400.
Probiotics in Intestinal Mucosal Healing: A New Therapy or an Old Friend?.
Filidou E, Kolios G Pharmaceuticals (Basel). 2021; 14(11).
PMID: 34832962 PMC: 8622522. DOI: 10.3390/ph14111181.
Probiotic-Induced Tolerogenic Dendritic Cells: A Novel Therapy for Inflammatory Bowel Disease?.
Ghavami S, Aghdaei H, Sorrentino D, Shahrokh S, Farmani M, Ashrafian F Int J Mol Sci. 2021; 22(15).
PMID: 34361038 PMC: 8348973. DOI: 10.3390/ijms22158274.